Bioscience Americas Is Poised to Lead the Global Medical Tourism

Bioscience Americas Is Poised to Lead the Global Medical Tourism

Bioscience Americas, LLC (, the leading international developer of autologous stem cell treatment centers, has positioned itself to capture a significant share of the global medical tourism market.
Estimated to reach $120 billion in two years, the market for medical tourism is projected to continue to increase substantially over the next decade.

Bioscience Americas and its scientific research partner the Global Institute of Stem Cell Therapy and Research (GIOSTAR) are currently involved in implementing autologous, or adult, stem cell clinics in Colombia and Costa Rica. Additional clinics are projected to be opened in Brazil and Chile in South America and on Native America tribal land within the United States. The goal is to open these additional clinics within the next twenty-four months.

The company has developed a medical tourism marketing program that is multi-faceted and is designed to attract a significant patient count.

Bioscience Americas CEO Eric Stoffers said that the program is entitled “Solutions for a Healthier World” and reflects the company’s mission to lead a worldwide healthcare revolution in the delivery of treatment protocols.

“We are experiencing a paradigm shift in healthcare away from surgery and medications. Our stem cell procedures treat autoimmune diseases without resorting to these costly alternatives,” Mr. Stoffers noted.

He continued that the company’s vision is to “take the treatments and therapies out of the lab and bring them to the marketplace. We have done this by focusing our marketing plan on several key components.” These components include affiliated and unaffiliated hospital referrals, physician referrals, medical professional continuing education programs, patient support networks, and an expanded social media presence among other strategies.

Bioscience Americas President Bill Deegan added that “as the plan unfolds we expect to see a significant increase over time in patient counts.

The Bioscience Americas/GIOSTAR partnership treats autoimmune diseases using regeneration technologies. More than 4,000 patients have already been treated at the GIOSTAR clinic in India.

Bioscience Americas is the development partner of GIOSTAR. They joint venture with GIOSTAR to develop stem cell treatment clinics.

The Global Institute of Stem Cell Therapy and Research is a worldwide consortium of renowned stem cell scientists and researchers. Based at the University of California in San Diego, it maintains research affiliations with major universities and institutions around the world. It has been the recipient of more than $400 million in research funding.

Source :